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MicroRNA-29aa b s t r a c t
Recent studies demonstrated that the mammalian heart possesses some capacity to proliferate. We
observed cardiomyocyte proliferation within 4 weeks of age (P4W) in rats. We found 95 microRNAs
that are differentially expressed in P4W cardiomyocytes. MicroRNA-29a was among the most highly
up-regulated microRNAs in P4W cardiomyocytes. Overexpression of microRNA-29a suppressed the
proliferation of H9c2 cell line. MicroRNA-29a inhibition induced cardiomyocytes to proliferate,
accelerated the G1/S and G2/M transition, and up-regulated the cell cycle gene expression. Cyclin
D2 (CCND2) was identiﬁed as a direct target of microRNA-29a. These ﬁndings indicate that microR-
NA-29a is involved in cardiomyocyte proliferation during postnatal development.
Crown Copyright  2013 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
It has long been thought that mammalian cardiomyocytes exit
the cell cycle soon after birth and become terminally differentiated
in the adult [1]. Recent studies indicated that postnatal mamma-
lian cardiomyocytes are still capable of substantial plasticity [2].
The capability of the cardiomyocyte to proliferate is lost by 7 days
of age in mouse [3] and a rapid switch from hyperplasia to hyper-
trophy in rat cardiomyocyte occurred within 3–5 days after birth
[4]. In human heart, the capability to undergo proliferation is lost
3–6 months after birth [5]. Although many efforts have been made
to understand the postnatal development and maturation in theheart [6], the potential mechanisms that regulate postnatal cardio-
myocytes proliferation are still poorly understood.
MicroRNAs (miRNAs, miRs) are a class of endogenous evolu-
tionarily conserved small (18–22 nucleotides) non-coding RNAs
[6,7], which have emerged as pivotal regulators in cell prolifera-
tion, differentiation and apoptosis [7,8]. Some differentiation asso-
ciated miRNAs have been reported to coordinately restrict
oncogene-induced proliferation [9]. miR-29 has displayed the
capacity for posttranscriptional regulation in myoblast [9] and
rhabdomyosarcoma [10]. During cardiomyocyte postnatal devel-
opment, miRNAs were reported to involve in cardiomyocyte prolif-
eration [11,12].
In this study, we ﬁrst characterized the proliferation pattern of
cardiomyocytes during the postnatal development. Then we inves-
tigated the miRNA and mRNA expression proﬁles in isolated
cardiomyocytes from postnatal day two (P2) and P4W groups.
We identiﬁed miR-29a as one of the most robustly up-regulated
miRNAs in P4W cardiomyocytes and found that miR-29a could
suppress cardiomyocytes proliferation. CCND2 was identiﬁed as a
miR-29a target which may be involved in the process of cardiomy-
ocyte cell cycle and proliferation regulation.
Fig. 1. Immunoﬂuorescence staining of the expression of Ki-67 (green), H3P (green) and troponin T (red) in the heart of rats. (A) Sections from various postnatal stages were
stained to label proliferating and mitotic cardiomyocytes (scale bars = 50 lm). Nuclei were stained by DAPI (blue). Quantiﬁcation of the numbers of Ki-67 (B) and H3P (C)
positive cardiomyocytes at sequential postnatal stages is shown. Values are presented as mean ± S.E.M., ⁄,#P-value < 0.05 vs. P1, n = 3.
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2.1. Animals and cell lines
All animal procedures were conducted in accordance with hu-
mane animal care standards approved by the Institutional Animal
Care Committee of Fuwai Hospital and Fuwai hospital Ethics Com-
mittee (Beijing, China). Ventricular cardiomyocytes were isolated
from Sprague–Dawley rats (Animal Laboratory Center of Peking
University Health Science Center, China) as described previously
[13,14]. H9c2 cells (CRL-1446) were from ATCC (American Type
Culture Collection, MD, USA).
2.2. Rat cardiomyocytes isolation and culture
Left ventricular cardiomyocytes were isolated with enzymatic
dissociation of the whole heart from rats on a Langendorff appara-
tus as described before [15]. Brieﬂy, cardiomyocytes were isolated
by antegrade collagenase perfusion and puriﬁed by differential
centrifugation as described [16,17]. After standard culture for
48 h, cardiomyocyte purity was analyzed on the BD FACSCalibur™
ﬂow cytometer (Supplementary Fig. S1A) and immunoﬂuorescence
(Supplementary Fig. S1B) as previously described [18]. More than
95% of cardiomyocytes were positive for the cardiomyocyte spe-
ciﬁc marker.
2.3. miRNA microarray, mRNA microarray, and GO-network
Total RNA was extracted from cardiomyocytes using Trizol
(Invitrogen, Carlsbad, CA, USA). miRNA and mRNA microarray
hybridizations were performed in triplicate with total RNA using
the Affymetrix miRNA microarray service (miRNA 2.0) and RatGenome 230 2.0 Array (Affymetrix, CA, USA) in CapitalBio (Beijing,
China) (Supplementary Materials and methods).2.4. Cell culture and transfection
H9c2 and cardiomyocytes were cultured and a subcultivation
ratio of 1:3 was used for further culture before cells researched
the 70% conﬂuent state [19]. Transfection was performed using
the siPORT NeoFX transfection agent with miRNA mimics (a small,
synthetic, double-stranded RNAs used to mimic endogenous ma-
ture miRNAs) or inhibitors (a small, synthetic, single-stranded
RNAs used to inhibit mature miRNAs for functioning), according
to the manufacturer’s instructions (Applied Biosystems, CA, USA)
(Supplementary Materials and methods).
2.5. Cell proliferation assay
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(MTS, Promega, Madison, WI, USA) was conducted to evaluate
the effect of miRNAs on H9c2 proliferation, following the manufac-
turer’s instructions. The absorption was determined at 490 nm on a
microplate reader (Model 680; BioRad, Tokyo, Japan).
2.6. RNA extraction and quantitative reverse transcription-PCR
Total RNA was extracted with Trizol reagent (Invitrogen, Carls-
bad, CA, USA). QRT-PCR was performed using an ABI 7300 cycle
detection system. MicroRNA Reverse Transcription kit and TaqMan
probes (Applied Biosystems) were used for miRNA RT-PCR. Data
were analyzed using the 2DDCT method [20,21] and the fold
changes of miRNA or mRNA expression were normalized to U6
Fig. 2. MicroRNA expression proﬁling in cardiomyocytes during postnatal cardiac development. (A) Heap-map depicts miRNAs that are either up-regulated or down-
regulated between P2 and P4W cardiomyocytes. Y-Axis represents the normalized arbitary microarray hybridization signal. (Green): lower expression; (red): higher
expression. (B) Total numbers of miRNAs up-regulated (ratioP 2) or down-regulated (60.05) were illustrated in pie. (C) Temporal regulation of six miRNAs in ventricular
tissues during postnatal development. Expression levels of each miRNA are normalized to U6 and represented as a fold change relative to P2 ventricular tissue. (D) Temporal
regulation of six miRNAs in cardiomyocytes. Each sample was tested in triplicate. Expression levels of each miRNA are normalized to U6 and represented as a fold change
relative to P2 cardiomyocytes. ⁄,#P-value < 0.05 vs. P2, n = 3.
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Primers are listed in Supplementary Table S1.
2.7. Immunoﬂuorescence staining and analysis
Hearts were isolated from rats and divided into different groups
(days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 21, 28). Sections (5 lm thickness)
were processed for immunoﬂuorescence according to the standard
procedures [12] (Supplementary Materials and methods).
2.8. Cell cycle analysis
Neonatal cardiomyocytes were cultured for 48 h in 6-well
plates (0.5  106 cells per well), synchronized for 24 h and then
transfected with miR-29a mimics or inhibitors. The detailed proce-
dures were performed as previously described [22] (Supplemen-
tary Materials and methods).
2.9. Western blot analysis
20 lg of lysate was separated by 12.5% SDS–PAGE and trans-
ferred to nitrocellulose. Antibodies to cyclin D2 (diluted 1:400 inTBST) and b-actin (diluted 1:1000 in TBST) were purchased from
Abcam (Cambridge, UK). Secondary antibody was labeled with
far-red-ﬂuorescencent Alexa Fluor 680 dye (Supplementary Mate-
rials and methods).
2.10. Luciferase reporter assays
PsiCHECK™-2 based vectors (Promega) were used to construct
the reporters (PMIR-REPORT). The fragment of the 30untranslated
region (30UTR) of CCND2 mRNA containing the putative (WT) or
mutated (MU) miR-29a binding sequence was used to construct
the vectors. The sequences of miR-29a binding site and mutant
sites were: WT (50-GAAGAAGAAGATTTT  TGGTGCTG-30) and mu-
tated (MUT: 50-GAAGAAGAAGATTTT  CAACAAGG-30). The miR-
29a binding sites were constructed using the XhoI and notI restric-
tion sites of PMIR-REPORT. HEK 293T cells (1  105) were seeded
to 24-well and transfected with lipofectamine 2000 (Invitrogen),
according to the manufacture’s instructions. After transfection for
48 h, relative luciferase measurements were determined with the
dual Luciferase Reporter Assay system (Promega, Madison, USA)
for the ﬁreﬂy and renilla luciferase activity of triplicate wells in
luminescence plate reader.
Fig. 3. miRNA–mRNA anti-correlated sets pathways. Representative network of differentially expressed miRNAs and mRNAs involved in cell cycle (A) and cell proliferation
(B) during cardiomyocyte postnatal development. Box nodes represent upregulated miRNA (red), cycle nodes (blue) represent downregulated mRNAs and signal transduction
pathway are also involved.
Fig. 4. Effects of six miRNAs on H9c2 proliferating. Overexpression of miR-29a
inhibits H9c2 cell proliferation, while downregulation of miR-29a promotes
proliferation. The absorbency were divided by the respective absorbance and
presented in percentage, relative to the negative control (n = 4). #P-value < 0.05 vs.
pre-miRNA control, ⁄P-value < 0.05 vs. anti-miRNA control.
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All the experiments were repeated at least three times and the
data are shown as mean ± S.E.M. Signiﬁcance was determined by
using the Student t-test for comparison of two groups and one-
way ANOVA for multiple comparison in SPSS 13.0 analysis (SPSS
Inc, Chicago, IL, USA). P values less than 0.05 were considered sta-
tistically signiﬁcant.
3. Results
3.1. Age-dependent expression of proliferation cardiomyocytes during
postnatal development in rats
The temporal sequence of cardiomyocytes proliferation was
characterized. The number of Ki-67 positive cardiomyocytes wasdecreased at day 10 (69 ± 9 vs. 114 ± 6 at day 1) (Fig. 1A and B). To-
tal mitotic indices determined by H3P were almost threefold lower
than Ki-67 staining. The number of H3P positive cardiomyocytes
was signiﬁcantly decreased at day 7 (almost threefold lower,
10 ± 3 vs. 32 ± 3 at day 1, Fig. 1A and C). These data suggest that
the proliferation and mitotic potentials of cardiomyocytes has
gradually disappeared after birth.
3.2. Comparative analysis of miRNA and mRNA proﬁle
The pattern of altered miRNA expression between P2 and P4W
was signiﬁcantly distinct (Fig. 2A). 95 miRNAs were differentially
regulated in P4W group (at least twofold) (Supplementary
Table S2). 7.7% (30/389) of miRNAs displayed increasing expres-
sion and 16.7% (65/389) decreasing expression (Fig. 2B). Multiple
large miRNA families were up-regulated, including the miRNA-
29, miRNA-30 and miRNA-133 families. mRNA expression in
P4W was also clustered together and separated from P2 (Supple-
mentary Fig. S2A and B).
3.3. Correlation between differentially expressed miRNAs and mRNAs
proﬁling
Among the transcripts that were signiﬁcantly repressed in P4W
cardiomyocytes, gene ontology cluster analysis revealed a striking
enrichment for genes involved in cell proliferation (Supplementary
Fig. S2B). Through the biostatistitical and pathway analysis, we
found two important pathway networks, which were involved in
cell cycle (Fig. 3A) and cell proliferation (Fig. 3B). The most highly
interconnected modules included several miRNAs: miR-1, miR-29,
miR-30, miR-34a, miR-139, miR-185. Besides, those miRNAs were
also found to be increased in P4W cardiomyocytes (at least two-
fold) (Supplementary Table 2). These ﬁndings help us to focus on
cardiomyocytes proliferation and choose the above six miRNAs
for further investigation. Those miRNAs were validated in heart tis-
sues harvested at multiple time points after birth (Fig. 2C). One of
the most highly upregulated miRNAs between P2 and P4W was
Fig. 5. MiR-29a inhibition induces cell cycle re-entry in neonatal cardiomyocytes. (A) Representative cardiomyocytes stained with Ki-67 (green) and a-actin (red) after
miRNA transfection in low (scale bars: 50 lm, up) and high (scale bars: 25 lm, down) magniﬁcation. Nuclei are stained with DAPI. (B) Quantitative analysis showed more
Ki-67 positive cardiomyocytes in the miR-29a inhibition group. (C) qRT-PCR data of CCND2 and CDK2 expression after miRNAs transfection. Expression levels are normalized
to GAPDH. Data are expressed as mean ± S.E.M., P-value < 0.05 for ⁄⁄, ⁄ and #, compared with respective controls. Pc, Pre-control; P29a, Pre-miR29a; Ac, Anta-control; A29a,
Anta-miR-29a. Arrow indicates proliferating cardiomyocyte.
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cardiomyocytes during the same period (Fig. 2D).
3.4. miR-29a inhibits H9c2 cell proliferation
H9c2 cell lines, a rat myoblast cell line derived from embryonic
hearts, were used in miRNAs functional screening to determine the
function of miRNA in cardiomyocytes proliferation. FAM™ dye la-
belled miRNA and qRT-PCR assays were used to determine the
transfection efﬁciency. After miRNA mimic and inhibitor transfec-
tion, the expression levels of miRNAs increased (>10-fold) and de-
creased (<10%), respectively (Supplementary Fig. 3A and B). The
overexpression of miR-1, miR-34a, miR-30e, miR-139 and miR-
185 in H9c2 could not increase cell proliferation 24 h after the
transfection compared with H9c2 transfected with the controls.
However, overexpression of miR-29a could signiﬁcantly suppress
the proliferation of H9c2, while inhibition of miR-29a would pro-
mote the proliferation of H9c2 (Fig. 4).
3.5. Effects of miR-29a on cardiomyocytes proliferation
To further investigate whether miR-29a could regulate the pro-
liferation of cardiomyocytes, we transfected the neonatal cardio-
myocytes with miR-29a and its inhibitor; then we assessed the
proliferation by Ki-67 staining. We found that miR-29a overex-
pression (P29a) could decrease cardiomyocytes proliferation 48 h
after transfection compared with cells transfected with a control
mimic (Pc) (Fig. 5A). Compared with a control inhibitor (Ac),
miR-29a inhibitor (A29a) signiﬁcantly promoted the proliferation
of cardiomyocyte (Fig. 5A). Quantiﬁcation of Ki-67 positive cardio-myocytes revealed a threefold increase (14.9 ± 0.3% vs. 4.9 ± 0.3%)
after miR-29a inhibitor transfection than the control inhibitor
(Fig. 5B). Cell cycle regulators have been implicated in cardiomyo-
cytes proliferation. Herein, we detected the expression of two cell
cycle-speciﬁc proteins, CCND2 and CDK2 in miR-29a transfected
cardiomyocytes. CCND2 and CDK2 gene expression were down-
regulated after miR-29a transfection, but up-regulated when trea-
ted with miR-29a inhibitors (Fig. 5C and D).
To demonstrate whether miR-29a also increased cardiomyo-
cytes mitosis, we stained for histone H3 phosphorylated on serine
10 (H3P), a G2/mitosis marker, in miR-29a transfected neonatal
cardiomyocytes. We found that miR-29a inhibition resulted in a
threefold increase in H3P-positive cardiomyocytes (4.2 ± 0.6% vs.
1.5 ± 0.3%) (Fig. 6A and B). To further investigate the antiprolifera-
tion effect of miR-29a on cardiomyocyte, we examined the effect of
miR-29a on cell cycle progression. miR-29a inhibition reduced the
amount of cardiomyocytes in G0/G1 phase, but increased the frac-
tion of cells resided in S and G2/M phases, in comparison to control
inhibitor (Fig. 6C and D). Taken together, these results suggested
that miR-29a inhibition could induce cardiomyocytes proliferation.
miR-29a alters the proliferation of cardiomyocytes potentially
through the modulation of cell-cycle progression.
3.6. miR-29a directly inhibits the expression of CCND2 via its 30UTR
We used the TargetScan (http://www.targetscan.org) to predict
the candidate target genes for miR-29a and found that CCND2 is
among the top predicted targets, with a conserved site for miR-
29a (Fig. 7A). Compared with the negative control, the luciferase
activity for CCND2-WT-transfected cells decreased about 55% in
Fig. 6. MiR-29a inhibition induces mitosis and cell cycle progression in cardiomyocytes. (A) Representative images of cardiomyocyte stained for H3P (green) and a-actin (red)
after miRNAs transfection. (B) Quantitative analysis showed more H3P positive cardiomyocytes in the miR-29a inhibition group. (C) Representative images of cell cycle
analysis after miRNAs transfection. (D) Flow cytometry analysis of cardiomyocytes stained with propidium iodide (PI) (n = 3). Data are presented as mean ± S.E.M., P-
value < 0.05 for ⁄, #, and $, compared with respective controls. Arrow indicates mitosis cardiomyocyte.
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were inhibited by the overexpression of CCND2 at the presence
of the wild type 30UTR but not by the mutations (Fig. 7B). To fur-
ther determine the expression of CCND2 in cardiomyocytes, we
collected cardiac ventricles from P2 and P4W rats and calculated
the number of CCND2 positive cardiomyocytes. Immunoﬂuores-
cence staining suggested that the number of CCND2 positive
cardiomyocytes was obviously downregulated in cardiomyocytes
in P4W rat (Fig. 7C and D). Furthermore, we determined the CCND2
protein expression in cardiomyocytes 48 h after miR-29a transfec-
tion by western blot. miR-29a overexpression could signiﬁcantly
suppressed CCND2 expression, while miR-29a inhibition up-regu-
lated CCND2 expression (Fig. 7E and F). These data suggested that
CCND2 is downregulated during the postnatal development and
miR-29a targets CCND2 by binding to its 30UTR and negatively reg-
ulated cardiomyocytes proliferation.4. Discussion
Before cardiomyocytes cease dividing and become terminally
differentiated, they still have the ability to proliferate [23]. Here,
we show that cardiomyocytes proliferative and mitosis activity re-
mained constant during the ﬁrst several days. The transition is
rather abrupt in postnatal day 10 and day 7 for proliferation and
mitosis. This proliferation pattern is not consistent with the earlier
observations in isolated cardiomyocytes, the proliferation capacityof which was lost within the ﬁrst 3–4 days [4]. This discrepancy
might be due to the possible effects of various factors on the pro-
liferation of cardiomyocytes in vitro.
Our combined miRNA/mRNA expression proﬁles discriminated
several important miRNAs involved in the postnatal development.
A handful of miRNAs involved in cell cycle and cell proliferation
regulation were upregulated in P4W cardiomyocytes. miR-29a
was one of the most highly up-regulated miRNAs in P4W. The pre-
cise time of miR-29a up-regulation was around postnatal day 10, a
time point that coincides with the onset of Ki-67 cardiomyocytes
downregulation.
Mature miR-290s are highly conserved among different species
[24]. It has been reported that miR-29a was involved in many
physiological and pathological processes. In the hematopoiesis sys-
tem, miR-29a was found to promote progenitor proliferation
through expediting G1 to S/G2 transitions [25]. A recent study
determined miR-29a as an important tumor suppressor in acute
myeloid leukemia by regulating the expression of Ski [26]. Marzi
et al. [9] found a subset of differentiation associated miRNAs
(miR-1, miR-34, miR-22, miR-365, miR-29, miR-145, and Let-7)
acted coordinately to regulate cell cycle associated gene expression
in cancer research. Besides, one excellent study [10] showed that
miR-29 can regulate the expression of CCND2 and other cell cycle
regulator to decrease cell proliferation. We found that miR-29a
was temporally up-regulated and miR-29a inhibition resulted in
neonatal cardiomyocytes entering the cell cycle. These anti-prolif-
erative effects of miR-29a on cardiomyocytes appeared to be med-
Fig. 7. MiR-29a directly targets CCND2. (A) Putative binding sites for rat miR-29a in the 30UTR of CCND2 and its seed sequence mutant (red). (B) Rat CCND2 gene 30UTR
luciferase activity was inbibited by miR-29a, but had no effect on CCND2 30UTR mutant. (C) Sections from postnatal hearts at P2 and P4W stained with cyclin D2 (CCND2;
green) and cardiac troponin T (red) to label cardiomyocytes (scale bars = 50 lm). (D) Quantiﬁcation of the number of CCND2 cardiomyocytes per ﬁeld in P2 and P4W hearts is
shown. Data are presented as cells/ﬁeld for six ﬁelds per heart for n = 3 samples per group, ⁄P < 0.05 vs. P4W group. (E) Immunoblots for CCND2 in cardiomyocytes transfected
with miR-29a mimics or inhibitors. (F) CCND2 protein expression is down-regulated by overexpression of miR-29a but is up-regulated by miR-29a inhibitors. ⁄P < 0.05 vs. Pc
group. &P < 0.05 vs. Ac group. #P < 0.05, compared with the normalized luciferase activity of control cells.
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important for us to consider new strategies to control cardiomyo-
cyte proliferation and open new approaches to cardiomyocyte cell
cycle regulation.
Limitations still exist in the present study. First, our results
showed that inhibition of miR-29a could promote proliferation in
neonatal cardiomyocyte. How miR-29a inhibition responds in the
neonatal 10 days cardiomyocytes is still unknown, as the prolifer-
ation capacity in rat heart is lost around the ﬁrst 10 days. In the
present study, we reported the proliferative effects of miR-29a
inhibition on cardiomyocytes appeared to be mediated through
the cell cycle progression. However, these proliferation effects re-
ported could also be mediated through other cell cycle arrest
checkpoint. Further efforts should be made to explore other targets
of miR-29a to fully understand the role of miR-29a in cardiomyo-
cyte proliferation.
In summary, our study identiﬁed a previously unrecognized
role of miR-29a in determining cardiomyocyte proliferation and
indicated that miR-29a inhibition could provide potential thera-
peutic usage for cardiac cell cycle regulation.
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